2017 Small-Cap Biotech Watchlist: Takeaways for Investors

Source: The Life Sciences Report  (01/18/2017)
2017 Small-Cap Biotech Watchlist: Takeaways for Investors
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. read more >

Time to Go Long on BrainStorm Cell Therapeutics?

Contributed Opinion
Source: Jason Napodano CFA of BioNap Inc. for The Life Sciences Report  (01/16/2017)
Time to Go Long on BrainStorm Cell Therapeutics?
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. read more >

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist

Source: The Life Sciences Report  (01/03/2017)
19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. read more >

Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries

Source: The Life Sciences Report  (12/21/2016)
Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries
The last several months have been active ones for Viveve: The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third-quarter financial results beat expectations, and the Viveve system has received regulatory approvals in Brazil, U.A.E. and Lebanon and FDA 510(k) clearance in the U.S. read more >

VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma

Source: The Life Sciences Report  (12/21/2016)
VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma
VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco. read more >

Disruptive Biotech and Technology Platform Sets Up 3D Signatures for Explosive Growth

Source: The Life Sciences Report  (12/14/2016)
Disruptive Biotech and Technology Platform Sets Up 3D Signatures for Explosive Growth
3D Signatures, a Canadian company developing a platform of "disruptive" personalized prognostic tests for patients with 13 different cancers and Alzheimer's disease, has attracted the attention of several stock watchers with its most recent announcements. read more >

Reliq Health Technologies Pilots Remote Patient Monitoring Program

Source: The Life Sciences Report  (12/07/2016)
Reliq Health Technologies Pilots Remote Patient Monitoring Program
Reliq Health Technologies is initiating a trial of its remote patient monitoring system with The Feldman Institute in Louisiana, the fourth program for the company's innovative technology. read more >
Expert Investing Ideas
Alphanorth Capital Conference 2017
NASDAQ Biotech ARCA Pharmaceutical

Can Biotech's Trump Bump Last?

Source: The Life Sciences Report  (12/02/2016)
Can Biotech's Trump Bump Last?
In the weeks since Donald Trump's presidential election victory, the stock markets have ridden a wave into positive—and in the case of the Dow, record-breaking—territory. The so-called Trump Bump also sent biotech indices, flaccid for much of the year, up as much as 15%. With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office. read more >

Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena

Source: The Life Sciences Report  (11/14/2016)
Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena
By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals has expanded its reach into the "high-value" field of immuno-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi's future. read more >

Why the Election Is Not as Relevant to Drug Stocks as You Might Believe

Contributed Opinion
Source: Dr. Len Yaffe for The Life Sciences Report  (11/02/2016)
Why the Election Is Not as Relevant to Drug Stocks as You Might Believe
Due to drug pricing controversies, there has been much concern about how the outcome of the upcoming election will affect pharmaceutical stocks. Dr. Len Yaffe of Stoc*Doc Partners sheds light on the issues in this analysis of drug price negotiation policy, and focuses in on one California ballot proposition that aims to rein in costs. read more >

Exploring Solutions to Healthcare's Spending Crisis

Contributed Opinion
Source: Dr. Len Yaffe for The Life Sciences Report  (10/19/2016)
Exploring Solutions to Healthcare's Spending Crisis
Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. In this article for The Life Sciences Report, Dr. Len Yaffe of Stoc*Doc Partners reviews the issues and proposes some cures. read more >
Alphanorth Capital Conference 2017
Biotech Watchlist 2017